作者
Sandra P. D’Angelo,Dejka M. Araujo,Albiruni R. Abdul Razak,Mark Agulnik,Steven Attia,Jean‐Yves Blay,Irene Carrasco García,John A. Charlson,Edwin Choy,George D. Demetri,Mihaela Druta,Édouard Forcade,Kristen N. Ganjoo,John Glod,Vicki L. Keedy,Axel Le Cesne,David A. Liebner,Víctor Moreno,Seth M. Pollack,Scott M. Schuetze,Gary K. Schwartz,Sandra J. Strauss,William D. Tap,Fiona Thistlethwaite,Claudia Maria Valverde Morales,Michael J. Wagner,Breelyn A. Wilky,Cheryl McAlpine,Laura Hudson,Jean‐Marc Navenot,Tianjiao Wang,Jane P. F. Bai,Stavros Rafail,Ruoxi Wang,Amy Sun,Lilliam Fernandes,Erin Van Winkle,Erica Elefant,Colin Lunt,Elliot Norry,Dennis Williams,Swethajit Biswas,Brian Andrew Van Tine
摘要
Summary
Background
Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for the treatment of patients with HLA-A*02 and MAGE-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma. Methods
SPEARHEAD-1 was an open-label, non-randomised, phase 2 trial done across 23 sites in Canada, the USA, and Europe. The trial included three cohorts, of which the main investigational cohort (cohort 1) is reported here. Cohort 1 included patients with HLA-A*02, aged 16–75 years, with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (confirmed by cytogenetics) expressing MAGE-A4, and who had received at least one previous line of anthracycline-containing or ifosfamide-containing chemotherapy. Patients received a single intravenous dose of afami-cel (transduced dose range 1·0 × 109–10·0 × 109 T cells) after lymphodepletion. The primary endpoint was overall response rate in cohort 1, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumours (version 1.1) in the modified intention-to-treat population (all patients who received afami-cel). Adverse events, including those of special interest (cytokine release syndrome, prolonged cytopenia, and neurotoxicity), were monitored and are reported for the modified intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT04044768; recruitment is closed and follow-up is ongoing for cohorts 1 and 2, and recruitment is open for cohort 3. Findings
Between Dec 17, 2019, and July 27, 2021, 52 patients with cytogenetically confirmed synovial sarcoma (n=44) and myxoid round cell liposarcoma (n=8) were enrolled and received afami-cel in cohort 1. Patients were heavily pre-treated (median three [IQR two to four] previous lines of systemic therapy). Median follow-up time was 32·6 months (IQR 29·4–36·1). Overall response rate was 37% (19 of 52; 95% CI 24–51) overall, 39% (17 of 44; 24–55) for patients with synovial sarcoma, and 25% (two of eight; 3–65) for patients with myxoid round cell liposarcoma. Cytokine release syndrome occurred in 37 (71%) of 52 of patients (one grade 3 event). Cytopenias were the most common grade 3 or worse adverse events (lymphopenia in 50 [96%], neutropenia 44 [85%], leukopenia 42 [81%] of 52 patients). No treatment-related deaths occurred. Interpretation
Afami-cel treatment resulted in durable responses in heavily pre-treated patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma. This study shows that T-cell receptor therapy can be used to effectively target solid tumours and provides rationale to expand this approach to other solid malignancies. Funding
Adaptimmune.